MA-ASTADIA
23.3.2021 15:02:11 CET | Business Wire | Press release
In today’s environment, many organizations have a “Cloud First” strategy for deploying business applications. Since most of the important business applications reside on mainframes, moving these applications and databases to any Cloud platform requires expert skills and technology.
The combination of Astadia’s Replatforming solutions, plus the Anubex Refactoring capabilities, offers a complete mainframe migration RoadMap. Astadia now offers all solution sets required to migrate from any IBM Z Series, or Unisys ClearPath platform, to the Cloud platform of their choosing.
“This is an exciting time to be in the Mainframe Migration business. The rapidly shrinking pool of people with mainframe software and hardware skills has given a new sense of urgency to IT buyers. The shortage of these critical skills is exacerbated by the COVID-19 Pandemic,” said Scott G. Silk, Chairman and CEO of Astadia.
“With this wave of Cloud computing, organizations are rapidly moving their applications and databases from mainframes. The Cloud enables incredible software innovation and developer productivity, access to AI and Predictive Analytics, while only charging the client for the resources they consume,” said Mr. Silk.
“Combining the forces of Astadia and Anubex leads to a unique combination of sales and delivery power with an exceptional portfolio of solutions for the migration market. This team is ready to accompany the largest organizations on their journey to the Cloud and becomes an important player in the top tier of mainframe migration companies,” said Louis Heymans, Managing Director of Anubex.
The acquisition of Anubex by Astadia allows the Anubex R&D team to continue to focus on extending their portfolio of products (CodeTurn, DataTurn, TestMatch and DataMatch) to automate refactoring and testing of legacy systems. The development of these products started well over 20 years ago, and today includes legacy technologies such as Assembler, COBOL, IDMS and Natural ADABAS that can be migrated to, among others, Java or C# in combination with all the leading SQL-databases – with the resulting applications ready for deployment in the (public) Cloud. These solutions using a Cloud-based “Migration Factory” model will be available to Astadia partners and clients worldwide.
For more details, take advantage of Astadia’s FREE Mainframe-to-Cloud Modernization Guide series, where we assist our clients as they plan and move into a safe and secure, high performance, cloud environment. This series covers IBM (NYSE:IBM) and UNISYS (NYSE:UIS) mainframes, and all popular target Cloud Platforms.
In these Mainframe-to-Cloud Migration Guides , readers will explore 20 pages of:
- Why migrate mainframe applications & databases to the Cloud?
- The challenges associated with mainframe modernization
- Detailed diagrams of mainframe software mappings to Cloud Platforms
- Programming languages & database translation tables
The Mainframe-to-Cloud Guide series is FREE , and may be downloaded.
Click on this link to view the Astadia Mainframe-to-Cloud Modernization Guide Series.
For more information visit http://www.astadia.com and follow Astadia at @AstadiaInc , Facebook/AstadiaInc , LinkedIn/Astadia
About Anubex
Anubex is an industry leader providing core software solutions, know-how, and support for complex mainframe-to-cloud migration and modernization projects.
With over 25 years of experience, demonstrated solutions and high-performing software tools, we help enterprises and government organizations boost their innovation capacity, competitiveness and agility by accelerating their digital transformation.
We are migration specialists, independent of the legacy or target technology stack. Our core competence lies in the know-how, the unique software solutions, and the extensive experience in how complex migration projects should be undertaken: what the stages and steps are, how the project should be structured, what the typical pitfalls and risks are, and how processes should be automated.
Our automated conversion and testing tools , combined with an innovative migration methodology , enable our team to support complex modernization projects and be one of the most competitive and reliable migration companies in the world.
Contacts / Headquarters
www.anubex.com
Anubex HQ
Anubex NV
Veldkant 13
2550 Kontich
Belgium
+32 3 450 42 50
migrations@anubex.com
About Astadia
Astadia is the market leading mainframe modernization consulting and systems integration boutique. A worldwide IT consulting firm, we specialize in moving IBM and Unisys mainframe applications and databases to distributed and cloud platforms. In fact, we were recently named Microsoft’s Mainframe-to-Azure partner of the year. Clients select Astadia for the following reasons: mainframe to cloud market focus, 28 years of mainframe experience, and hybrid READI methodology. Upon project completion, customers often select Astadia to manage their cloud environment as well. We have successfully completed over 200 mainframe modernization projects and are recognized industrywide as the mainframe to cloud experts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005241/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom